Business Context and Reporting Period
Company: BioTime, Inc. (Note: Input metadata referenced "Lineage Cell Therapeutics," but the filing text identifies the registrant as BioTime, Inc.)
Reporting Period: Quarter ended March 31, 2011
Business Overview: BioTime is a biotechnology company focused on regenerative medicine, specifically human embryonic stem (hES) and induced pluripotent stem (iPS) cell technology. The company operates through multiple subsidiaries targeting cancer, orthopedic disorders, neurological diseases, and vascular conditions. Historically, operating revenues have been derived almost exclusively from royalties and licensing fees related to its plasma volume expander product, Hextend®.
Key Financial Metrics
| Metric | Q1 2011 | Q1 2010 |
|---|---|---|
| Total Revenues | $824,629 | $768,086 |
| Net Loss (Consolidated) | $(3,944,685) | $(1,312,025) |
| Net Loss Attributable to BioTime | $(3,362,132) | $(1,286,764) |
| Loss Per Share (Basic & Diluted) | $(0.07) | $(0.04) |
| Cash and Cash Equivalents (End of Period) | $30,136,979 | $11,173,062 |
| Net Cash Used in Operating Activities | $(3,607,439) | $(1,226,581) |
| Total Assets | $56,890,231 | $53,272,659 |
| Accumulated Deficit | $(67,316,641) | $(63,954,509) |
Material Changes vs. Prior Period
- Revenue Growth: Total revenues increased 7.4% to $824,629, driven primarily by a significant increase in "Sale of research products" (from $2,764 to $88,448) and higher license fees. However, royalties from product sales (Hextend) decreased 27% to $215,971 due to lower sales volumes by licensees.
- Expense Surge: Total expenses more than doubled to $4.85 million from $2.09 million. Research and Development (R&D) expenses increased 146% to $2.86 million, and General and Administrative (G&A) expenses increased 114% to $1.99 million.
- Drivers of Expense Increase: The increase in R&D and G&A is largely attributable to the consolidation of new subsidiaries (ESI and Cell Cure Neurosciences) acquired in 2010, amortization of intangible assets ($456,152), and increased stock-based compensation.
- Acquisitions: The company completed two significant transactions in Q1 2011: the asset purchase of Cell Targeting, Inc. (January) and the merger with Glycosan BioSystems, Inc. (March). These transactions added significant intangible assets and equipment to the balance sheet.
Guidance, Outlook, and Risks
- Liquidity: The company holds approximately $30.1 million in cash. Management states that current revenues are insufficient to cover operating expenses, and additional debt or equity capital may be required to fund operations and clinical trials.
- Future Investments: BioTime plans to invest approximately $1.2 million over the next 12-14 months in the pre-clinical development of HyStem-Rx (acquired via Glycosan merger). Additionally, the company plans to invest an additional $1.166 million in its new subsidiary, LifeMap Sciences, by July 2012, contingent on milestones.
- Revenue Outlook: Royalty revenues from Hextend are expected to fluctuate based on licensee sales reports. The company is in early stages of commercializing stem cell research products and cannot yet predict revenue from these new lines.
- Risks: Key risks include the inability to attain profitability, the high cost and uncertainty of clinical trials, regulatory hurdles (FDA approval), and the potential need for dilutive equity financing. The company also faces risks related to the commercialization of the LifeMap Sciences database and the success of the stem cell industry.
Investor Verification Checklist
- Cash Burn Rate: Verify the sustainability of the $30.1 million cash balance against the current quarterly operating cash burn of ~$3.6 million.
- Acquisition Integration: Assess the progress of integrating Cell Targeting and Glycosan technologies into existing R&D pipelines and the timeline for HyStem-Rx clinical trials.
- Revenue Concentration: Monitor the trend of Hextend royalties, which remain the primary cash flow source, and the impact of competitive pricing on licensee sales.
- LifeMap Sciences Milestones: Track the achievement of development milestones required to trigger the additional $1.166 million investment commitment.
- Regulatory Status: Review the status of regulatory approvals for Hextend in new markets (Japan, Taiwan, China) and the FDA review process for new therapeutic candidates.